- RecruitingPHASE3
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
This study is looking at new treatments for a type of bladder cancer that has a high chance of coming back after surgery. It compares two new drugs, Dato-DXd and Rilvegostomig, with standard treatments to see if they are safer and more effective.
For: High-risk Muscle Invasive Urothelial CarcinomaUnited States · Australia · Brazil - Active not recruitingPHASE3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
This study is for people with a specific type of advanced breast cancer (PD-L1 positive triple-negative) that hasn't been treated yet. It compares two different drug combinations to see which one works better at stopping the cancer from growing.
For: Triple Negative Breast Cancer · PD-L1 PositiveUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This study is testing a new combination of two medicines, calderasib and pembrolizumab, for a specific type of lung cancer. We want to see if this combination works better than current treatments for people with advanced non-small cell lung cancer that has a particular genetic change.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
This study looks at a new way to give a lung cancer medicine called pembrolizumab. It compares giving it through a drip in your arm (IV) versus a new injection under the skin (SC) for people with advanced non-small cell lung cancer. Researchers want to see how the injection works.
For: Lung Cancer · Non-Small Cell Lung CancerUnited States · China · Germany - RecruitingPHASE3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
This study is testing a new drug, olomorasib, for a specific type of lung cancer (NSCLC) with a KRAS G12C gene change. It checks if olomorasib, combined with standard treatments, works better than standard treatments alone for people with either resected or unresectable cancer.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Austria - RecruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This study looks at a new drug combination, sacituzumab tirumotecan and pembrolizumab, for a type of breast cancer called triple-negative. It's for patients who had initial treatment but still have some cancer cells after surgery. We want to see if this new combination helps prevent the cancer from coming back better than standard care.
For: Triple-Negative Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
This study is for adults with head and neck cancer that has spread or returned. It tests if combining new medicines like BI 770371, pembrolizumab, and cetuximab can shrink tumors better than pembrolizumab alone. It aims to see if these combinations help the immune system fight cancer.
For: Head and Neck Squamous Cell CarcinomaUnited States · Australia · Brazil - RecruitingPHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This study looks at a new drug, olomorasib, combined with other treatments for advanced lung cancer. It’s for people whose cancer has a specific change called KRAS G12C and haven't had previous treatment for advanced disease. The aim is to see if this new combination works better than standard care.
For: Carcinoma, Non-Small-Cell Lung · Neoplasm MetastasisUnited States · Australia · Austria - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
This study looks at new treatments, sacituzumab tirumotecan alone or with pembrolizumab, for triple-negative breast cancer. It compares their effectiveness with standard chemotherapy to see if they help people live longer or stop cancer growth.
For: Triple Negative Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This study looks at new drug combinations for stomach or food pipe cancer that has spread. It compares an experimental treatment with standard care, aiming to find better ways to treat patients whose cancer has specific features.
For: Gastric Cancer · Gastroesophageal Junction CancerUnited States · Argentina · Australia - RecruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
For: Non-small Cell Lung Cancer · NSCLCUnited States · Argentina · Austria - Active not recruitingPHASE2
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
This study looks at a new drug, evorpacept, combined with pembrolizumab and chemotherapy for advanced head and neck cancer. It aims to see if this new combination is effective for patients who haven't had treatment for their advanced disease.
For: Head and Neck Cancer · Head and Neck Squamous Cell CarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
This study is testing a new cancer medicine, GEN1042, both by itself and with other treatments. It's for people with certain advanced solid tumours where standard treatments haven't worked or aren't available. The main goals are to check its safety and see how well it fights cancer.
For: Malignant Solid Tumor · Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC)United States · Denmark · France - Active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
For: Non-small Cell Lung CancerUnited States · Argentina · Austria - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
This study is comparing two treatments, belzutifan plus pembrolizumab, against pembrolizumab alone, for kidney cancer that has been removed. It aims to see if the combination treatment can prevent the cancer from returning.
For: Carcinoma, Renal CellUnited States · Australia · Brazil - RecruitingPHASE3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This study is looking at a new combination of medicines for a type of lung cancer that has spread or can’t be removed by surgery. It compares a drug called trastuzumab deruxtecan plus pembrolizumab to standard chemotherapy plus pembrolizumab.
For: Non-small Cell Lung CancerUnited States · Argentina · Belgium - Active not recruitingPHASE3
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
This study is testing two different combinations of medicines, volrustomig plus chemotherapy, or pembrolizumab plus chemotherapy, for people with an advanced type of lung cancer. The aim is to see which combination is safer and works better as a first treatment.
For: Metastatic Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
For: Non Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
This study is looking at new ways to treat advanced non-small cell lung cancer (a type of lung cancer) that has spread. It compares an experimental drug, rilvegostomig, with a standard drug, pembrolizumab, both given with chemotherapy, to see which works better and is safer.
For: Non-squamous Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
This study is testing a new medicine, vepugratinib, for advanced or spread bladder cancer. It will be given with two other drugs, enfortumab vedotin and pembrolizumab, to see if it's safe and helps. It’s compared to a dummy medicine (placebo).
For: Carcinoma, Transitional Cell · Urinary Bladder Neoplasms · Neoplasm MetastasisUnited States · Australia · Brazil - RecruitingPHASE3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
This study looks at a new combination treatment, Sigvotatug Vedotin plus pembrolizumab, for a type of lung cancer where a protein called PD-L1 is high. We want to see if this combination works better than pembrolizumab alone to help patients.
For: Non-Small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung (NSCLC)United States · Argentina · Australia - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
For: Advanced Non-Small Cell Lung Cancer · Metastatic Non-Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
This study looks at a new treatment for a type of breast cancer that has come back or spread. It combines a drug called pembrolizumab with standard chemotherapy to see if it works better than chemotherapy alone for HR+/HER2- breast cancer.
For: Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
For: Solid Tumors · Hematologic MalignanciesUnited States · Argentina · Australia - Active not recruitingPHASE2
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
This study looks at a new drug, evorpacept, combined with an existing one, pembrolizumab, for advanced head and neck cancer. It aims to see if this combination works better than pembrolizumab alone for patients who haven't had treatment for advanced stages of their cancer. It's a Phase 2 trial, meaning it's still in earlier stages of testing.
For: Head and Neck Cancer · Head and Neck Squamous Cell CarcinomaUnited States · Australia · Belgium - RecruitingPHASE2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This study is for cancer patients who are already taking part in another study using the drug adagrasib. It allows them to continue getting treatment if it's helping. It looks at how well adagrasib works long-term for various solid tumours, alone or with other cancer medicines.
For: Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
This study looks at new drug combinations (Dato-DXd with rilvegostomig) for a type of advanced lung cancer. It compares them to a standard treatment, pembrolizumab, to see if they work better and are safe as a first treatment option.
For: Non-Small Cell Lung CancerUnited States · Australia · Austria - RecruitingPHASE3
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
This study compares a new treatment called IMA203 with standard care for advanced skin melanoma that has already been treated. Its main goal is to see if IMA203 is more effective and safe for patients who have limited treatment options.
For: Melanoma, Cutaneous MalignantUnited States · Canada · France - RecruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
For: Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
This study looks at a new combination treatment for a type of brain cancer called glioblastoma. It combines a device called Optune, a chemotherapy drug called temozolomide, and a new drug called pembrolizumab, comparing it to Optune, temozolomide, and a dummy drug.
For: GlioblastomaUnited States · Canada · Czechia - RecruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This study is testing a new drug, VVD-133214, for advanced solid tumours, including a type of bowel cancer. It looks at safety, how the body handles the drug, and if it can help shrink tumours. It's an early-stage study, sometimes testing the new drug with other standard treatments.
For: Advanced Solid Tumors · Colorectal CancerUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
This study looks at a new treatment called Pumitamig for advanced non-small cell lung cancer that hasn't been treated before. It compares Pumitamig to an existing treatment, Pembrolizumab, in people whose cancer cells have a high level of a specific marker called PD-L1.
For: Non-Small Cell Lung Cancer (NSCLC)United States · Argentina · Australia - RecruitingPHASE3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
This study compares two treatments for a specific type of advanced lung cancer. It looks at how well a treatment combining sotorasib with chemotherapy works against one combining pembrolizumab with chemotherapy, focusing on extending life and preventing cancer growth.
For: Non-Small Cell Lung Cancer (NSCLC)United States · Argentina · Australia - Active not recruiting
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
This study looks at existing medical records of people in Europe and Canada with a type of lung cancer called non-small cell lung cancer (NSCLC) who had surgery. It helps us understand how a treatment called immunotherapy is used before or after their operation, and how they got on.
For: Non-Small Cell Lung CancerUnited Kingdom - RecruitingPHASE2
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
This study is for people with a type of bladder cancer that has grown into the bladder muscle. Doctors are looking at a new treatment with two medicines, Enfortumab Vedotin and Pembrolizumab, to see if it can help people keep their bladder instead of having surgery to remove it.
For: Muscle-invasive Bladder CancerUnited States · Germany · Japan - RecruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
This study looks at new treatments for a type of womb cancer that has spread or returned. It compares a new drug combination (sac-TMT with pembrolizumab) against pembrolizumab alone to see if it helps patients live longer and keeps the cancer from growing.
For: Endometrial CancerUnited States · Argentina · Australia - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
For: Metastatic Non-small Cell Lung Cancer With MTAP DeletionUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
This study is looking at a new combination of medicines, Dato-DXd and pembrolizumab, for advanced lung cancer. It compares this combination to pembrolizumab alone to see if it's more effective and safe for people whose cancer hasn't spread and who haven't had other treatments yet.
For: Metastatic Non Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
For: Advanced Non-small Cell Lung Cancer, HER2 MutationUnited States · Argentina · Australia - RecruitingPHASE1
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
This study is looking at a new medicine called LOXO-435 for cancers, especially bladder cancer, that have a specific gene change (FGFR3). It checks how safe and effective LOXO-435 is, both alone and with other standard treatments, to see if it can help patients.
For: Urinary Bladder Neoplasms · Neoplasm Metastasis · Ureteral NeoplasmsUnited States · Australia · Canada - Active not recruitingPHASE3
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study looks at a new drug, zongertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares zongertinib to standard treatment to see if it can better slow down cancer growth and improve how long people live without their cancer getting worse.
For: Lung Cancer, Non-squamous, Non-small CellUnited States · Argentina · Australia - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer (squamous non-small cell lung cancer) that has spread. It compares two different drug combinations, including a new medicine called rilvegostomig, to see if they can help patients live longer and improve their quality of life.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
This study is looking at new combinations of medicines for advanced lung or breast cancer. We want to see if they are safe, how much medicine gets into the body, and if they show early signs of working. It's for adults with certain types of advanced cancer.
For: Lung Cancer · Breast CancerUnited States · Australia · Canada - RecruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
For: Breast CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This study is testing a new combination of treatments for adults with advanced lung cancer (NSCLC) that hasn't spread to the brain or spine and doesn't have certain genetic changes. It compares this new treatment to a standard one, hoping it works better.
For: NSCLCUnited States · Austria · Brazil - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
This study is testing a new drug, rilvegostomig, against a standard treatment, pembrolizumab, for advanced lung cancer. It's for people whose cancer has spread and has high levels of a specific marker called PD-L1. The aim is to see which treatment works better and is safer.
For: Carcinoma, Non-Small Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
This study looks at new drug combinations for advanced bladder cancer. Doctors want to see if adding different medicines to pembrolizumab and enfortumab vedotin (EV) works better and is safe. The goal is to find new, effective treatments for patients.
For: Metastatic Urothelial Carcinoma · Urothelial NeoplasmsUnited States · Australia · Canada